Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-001 (AT-001) in hereditary cystatin C amyloid angiopathy
2023-503969-36-01Phase 2Authorised
- Sponsor
- Arctic Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of N-acetylcysteine amide in Hereditary cystatin C amyloid angiopathy (HCCAA) (2 arms), sponsored by Arctic Therapeutics. Primary endpoints: Safety and Efficacy. Planned start Mar 2024; status: authorised.
02
Drugs
N-acetylcysteine amide
03
Conditions
Hereditary cystatin C amyloid angiopathy (HCCAA)
Beyond the preview
Go deeper on 2023-503969-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503969-36-01.